From the publishers of JADPRO

Multiple Myeloma Resource Center


U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma

Last Updated: Tuesday, August 22, 2023

Accelerated approval of TALVEY™ (talquetamab-tgvs) was granted approval by the US FDA to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.  

PR Newswire
News & Literature Highlights

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations


Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis


Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)


Increased COVID-19 breakthrough infection risk after SARS-CoV-2 vaccine boosting in patients with plasma cell disorders: A large nationwide Veterans Affairs study

ASCO 2023

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

U.S. Food & Drug Administration

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

Leukemia and Lymphoma

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: A population-based study